Microtubule targeted therapeutics, imaging agents

New microtubule targeted compounds allow imaging, treatment of cancer

  • Microtubule-targeted radiopharmaceuticals
  • Images and treats cancer
  • Non-radioactive forms of the drugs can induce cell death
  • Can be labeled with a variety of radionuclides

 
Licensing manager: Matt Boehm, Ph.D.
mboehm@unmc.edu or 402-559-2166
 

Description

New microtubule targeted compounds allow imaging, treatment of cancer

UNMC researchers have developed compounds that are capable of not only imaging and monitoring tumors, but treating them as well.
 
The new compounds specifically bind to protein-based structures called microtubules. Microtubules play a critical role in a number of cellular functions, and are a key target for treating a variety of cancers.
 
UNMC’s compounds selectively target microtubules. The compounds can be safely labeled with various radioactive atoms that allow the compounds to be used for imaging (SPECT or PET) and therapy. When used without the radioactive isotopes, the compounds can help kill cancer cells and make them more susceptible to radiation therapy.
 
Microtubule-targeted compounds labeled with iodine-131 were tested in a mouse model of glioblastoma. Treatment with the compound significantly reduced tumor size and weight. Additional studies will look at the use of other radionuclides such as astatine-211.
 
To discuss licensing opportunities contact Matt Boehm, Ph.D., at mboehm@unmc.edu or 402-559-2166.
 

Additional Info

Publications

Intellectual Property

  • Provisional patent application filed